Changes of topoisomerase IIα expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival

Nicola Tinari, Rossano Lattanzio, Clara Natoli, Ettore Cianchetti, Domenico Angelucci, Enrico Ricevuto, Corrado Ficorella, Paolo Marchetti, Saverio Alberti, Mauro Piantelli, Stefano Iacobelli

Research output: Contribution to journalArticle

Abstract

Purpose: To assess the value of changes in the expression of topoisomerase IIα (TopoII) and the proto-oncogene erbB-2 (HER-2) as predictors of relapse-free survival in women with operable breast cancer treated with anthracycline-based neoadjuvant chemotherapy. Patients and Methods: Seventy-seven patients with primary breast cancer who had undergone neoadjuvant anthracycline-based chemotherapy were included in the present study. TopoII and HER-2 were measured by immunohistochemistry in prechemotherapy and postchemotherapy (at the time of surgery) tumor specimens, and the value of their changes as predictors of relapse-free survival were evaluated by Kaplan-Meier and Cox proportional hazard regression analyses. Results: Neoadjuvant chemotherapy resulted in a significant reduction in the percentage of cells expressing TopoII (P <0.0001). No significant change was observed for HER-2. TopoII and HER-2 expression before chemotherapy predicted tumor response to treatment. Changes in TopoII expression after chemotherapy were strongly associated with a poor relapse-free survival (P <0.0001) in a Cox multivariate analysis adjusted for other clinicopathologic prognostic factors. Conclusion: Changes in TopoII expression after anthracycline-based neoadjuvant chemotherapy is an independent predictor of a poor relapse-free survival in patients with breast cancer. Tumor cells displaying an increased TopoII expression after treatment may be responsible for relapses, and may, therefore, define a group of patients with anthracycline-resistant breast cancer.

Original languageEnglish
Pages (from-to)1501-1506
Number of pages6
JournalClinical Cancer Research
Volume12
Issue number5
DOIs
Publication statusPublished - Mar 1 2006

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tinari, N., Lattanzio, R., Natoli, C., Cianchetti, E., Angelucci, D., Ricevuto, E., Ficorella, C., Marchetti, P., Alberti, S., Piantelli, M., & Iacobelli, S. (2006). Changes of topoisomerase IIα expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clinical Cancer Research, 12(5), 1501-1506. https://doi.org/10.1158/1078-0432.CCR-05-0978